Mutated class II major histocompatibility proteins
OwnerDavid M. Kranz, Scott Starwalt +1inventors
InventorsDavid M. Kranz, Scott Starwalt, Jeffrey A. Bluestone
Life of this patent
Estimating the term…
Abstract
Provided are methods for directed mutagenesis and selection of MHC Class II proteins and single chain proteins with improved conformational stability and/or binding affinity for at least one cognate ligand. The improved proteins are useful for identification of T cells that are specific for the MHC Class II proteins and for treatment of disorders including autoimmune diseases, with the disorder determining the choice of the particular improved protein, peptide-protein complex or other ligand protein complex.
Claims25
A mutagenized combinatorial library of Major Histocompatibility Complex (MHC) Class II chimeric proteins displayed on the surfaces of recombinant yeast cells, wherein the mutagenized combinatorial library comprises at least one member MHC Class II protein which is improved in conformational stability or in peptide binding or T cell receptor binding as compared with a comparison MHC Class II protein which has not been mutagenized.
An isolated mutant MHC Class II chimeric protein, wherein said protein comprises a portion mediating binding to the surfaces of the recombinant yeast cells and a portion which comprises a peptide binding region of a MHC Class II protein and wherein said chimeric protein is improved in stability or in T cell receptor binding as compared with an MHC Class II chimeric protein which is not a mutant chimeric protein.
A method for treating or preventing an autoimmune disease in person or animal suffering from or susceptible to said autoimmune disease comprising the step of administering to the patient a therapeutically effective amount of an isolated mutant MHC Class II chimeric protein which is improved in conformational stability as compared with a comparison MHC Class II chimeric protein which is not mutant.
Dependencies are inferred from the claim text.